SANDRA M JOHNSON
Speech Language Pathology in Little Rock, AR
License number
Massachusetts 3648
Issued Date
Aug 6, 1993
Expiration Date
Jan 6, 1996
Type
Speech Language Pathologist
Address
Address
Little Rock, AR 72211
Professional information
Sandra Johnson - Little Rock, AR
Work:
Arkansas Department of Human Services
Local Office Administrative Assistant United States Forest Service / Job Corps - Royal, AR
Social Services Assistant Methodist Family Health Psychiatric Residential Treatment Ctr. - Little Rock, AR
Lead Behavioral Instructor
Local Office Administrative Assistant United States Forest Service / Job Corps - Royal, AR
Social Services Assistant Methodist Family Health Psychiatric Residential Treatment Ctr. - Little Rock, AR
Lead Behavioral Instructor
Education:
Hot Springs High School - Hot Springs, AR
High School Diploma in General
High School Diploma in General
Transportation/Trucking/Railroad Professional
Location:
Little Rock, Arkansas Area
Industry:
Transportation/Trucking/Railroad
Work:
dhl express
1990 - 2009
-
field services supervisor
Self Employed At Ghana Weaving
Position:
self employed at ghana weaving
Location:
Little Rock, Arkansas Area
Industry:
Capital Markets
Work:
ghana weaving
-
self employed
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
6350451, Feb 26, 2002
Filed:
Jun 25, 1999
Appl. No.:
09/344357
Inventors:
Thomas Dag Horn - Little Rock AR
Sandra Marchese Johnson - Little Rock AR
Sandra Marchese Johnson - Little Rock AR
Assignee:
The Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
A61K 3900
US Classification:
4241841, 4241931, 42419611, 4242011, 4242121, 4242741, 424 852
Abstract:
The present immunotherapy relates to a method of treating epithelial tumors and the pharmaceutical compositions and kits useful in treating such tumors. The immunotherapy comprises injecting an effective amount of a pharmaceutical composition containing at least one antigen into the tumor, wherein the antigen is selected for inducing or having the ability to induce a cutaneous delayed type hypersensitivity (DTH) response in the subject prior to the injection of the antigen into the tumors. This immunotherapy is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present immunotherapy are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. Additionally, the method optionally includes the injection of an effective amount of at least one cytokine or colony stimulating factor into the tumor either simultaneously with or sequentially to the injection of the antigen. The subject treated by the present immunotherapy is preferably a mammal selected from a human, canine, bovine, feline, equine, ovine or rabbit subject.
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
2002014, Oct 3, 2002
Filed:
Feb 25, 2002
Appl. No.:
10/081185
Inventors:
Thomas Horn - Little Rock AR, US
Sandra Johnson - Little Rock AR, US
Sandra Johnson - Little Rock AR, US
Assignee:
University of Arkansas
International Classification:
A61K039/295, A61K039/116, A61K039/12
US Classification:
424/204100, 424/201100, 424/203100
Abstract:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.
Patient Care Tech. At University Of Arkansas For Medical Sciences
Position:
Patient Care Tech. at University of Arkansas for Medical Sciences
Location:
Little Rock, Arkansas Area
Industry:
Research
Work:
University of Arkansas for Medical Sciences
-
Patient Care Tech.
Education:
Pulaski Technical College 2009 - 2012
Business in Office Technology, Business Communication, Accounting, Office Management
Business in Office Technology, Business Communication, Accounting, Office Management
Interests:
singing, planiting flowers, vollyball, fishing
Honor & Awards:
Employee of the month of 2008
Immunotherapy Of Epithelial Tumors Using Intralesional Injection Of Antigens That Induce A Delayed Type Hypersensitivity Reaction
US Patent:
7846447, Dec 7, 2010
Filed:
Mar 19, 2008
Appl. No.:
12/077508
Inventors:
Thomas Dag Horn - Little Rock AR, US
Sandra Marchese Johnson - Little Rock AR, US
Sandra Marchese Johnson - Little Rock AR, US
Assignee:
The Board of Trustees of the University of Arkansas - Little Rock AR
International Classification:
A61K 39/00
US Classification:
4241841, 514 2, 424 854
Abstract:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.